Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | CAR T-cells for myeloma: an update

Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Noopur Raje, MD, of Massachusetts General Hospital, Boston, MA, gives us an update on CAR T-cells for myeloma. Dr Raje discusses the results seen with bb2121, incuding toxicity, bone marrow MRD negativity and progression-free survival, and highlights the refractory nature of the patients that received this therapy. She also covers the key remaining questions for investigation.